Compare CEVA & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CEVA | DRTS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 607.1M |
| IPO Year | 2002 | N/A |
| Metric | CEVA | DRTS |
|---|---|---|
| Price | $19.69 | $7.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $33.25 | $8.00 |
| AVG Volume (30 Days) | ★ 339.9K | 299.3K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,507,000.00 | N/A |
| Revenue This Year | $14.97 | N/A |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.45 | N/A |
| 52 Week Low | $18.23 | $2.30 |
| 52 Week High | $36.95 | $7.89 |
| Indicator | CEVA | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 54.16 |
| Support Level | $19.30 | $6.90 |
| Resistance Level | $24.00 | $7.50 |
| Average True Range (ATR) | 1.25 | 0.49 |
| MACD | -0.23 | -0.08 |
| Stochastic Oscillator | 8.21 | 56.60 |
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.